A Phase 1 Study of ABL001 in Combination With Dasatinib and Prednisone in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML)
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Asciminib (Primary) ; Dasatinib (Primary) ; Prednisone
- Indications Chronic myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 06 Nov 2019 Results (n=6 ; as of 31 July,2019) assessing predictive biomarkers of response, released in 61st Annual Meeting and Exposition of the American Society of Hematology
- 16 Oct 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2021.
- 12 Oct 2018 Status changed from not yet recruiting to recruiting.